X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology. The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
Lead Product(s): EXG-5003
Therapeutic Area: Infections and Infectious Diseases Product Name: EXG-5003
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Elixirgen Therapeutics is currently conducting a Phase 1/2 trial of EXG-34217, an autologous cell therapy to treat patients with telomere biology disorders with bone marrow failure. The collaboration with Hitachi would result in the development of Micro GMP suites.
Lead Product(s): EXG34217
Therapeutic Area: Genetic Disease Product Name: EXG34217
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hitachi Global Life Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 26, 2023
Details:
EXG-34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure that uses Elixirgen Therapeutics’ proprietary ZSCAN4 technology to extend the telomeres of the patients.
Lead Product(s): EXG-34217,EXG-001
Therapeutic Area: Genetic Disease Product Name: EXG-34217
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
The partnership will leverage Elixirgen's proprietary ZSCAN4 therapy platform to advance treatments of aging-associated diseases. Elixirgen Therapeutics is currently performing a Phase I/II clinical trial using its ZSCAN4 therapy platform in disorders with bone marrow failure.
Lead Product(s): ZSCAN4-based Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Taisho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022
Details:
EXG-5003 is a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. EXG-5003 was optimized for intradermal injection with potential dose-sparing and safety benefits.
Lead Product(s): EXG-5003
Therapeutic Area: Infections and Infectious Diseases Product Name: EXG-5003
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Fujita Health University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
Elixirgen Therapeutics concluded on May 18 its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the company's COVID-19 vaccine candidate, EXG-5003.
Lead Product(s): EXG-5003
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
